Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference

Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) highlighted its LIBERTY Endovascular Robotic System at the International Symposium on Endovascular Therapy (ISET), Feb 9-12, 2026, where experts discussed single-use robotic solutions.

The company noted LIBERTY's FDA clearance, limited market release begun in late 2025, cross-specialty hospital use, and plans for a full market release at SIR in April 2026.

Positive

• Only FDA-cleared single-use endovascular robotic system
• Limited market release began in late 2025
• Used across multiple hospitals and specialties
• Full market release planned for April 2026 at SIR

Negative

• Currently in limited market release, not yet broadly available
• Commercial adoption remains early-stage despite growing interest

News Market Reaction

+4.50%

27 alerts

+4.50% News Effect

+13.7% Peak in 26 hr 35 min

+$7M Valuation Impact

$159M Market Cap

0.9x Rel. Volume

On the day this news was published, MBOT gained 4.50%, reflecting a moderate positive market reaction. Argus tracked a peak move of +13.7% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $159M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ISET conference dates: February 9–12, 2026 Planned full market release: April 2026

2 metrics

ISET conference dates February 9–12, 2026 International Symposium on Endovascular Therapy in Miami Beach, Florida

Planned full market release April 2026 Target timing for full LIBERTY market release at SIR conference

Market Reality Check

Price: $2.17 Vol: Volume 2,628,141 vs 20-da...

normal vol

$2.17 Last Close

Volume Volume 2,628,141 vs 20-day average 2,310,717, indicating slightly elevated trading activity. normal

Technical Price $2.00 is trading below the 200-day MA at $2.60, indicating pre-news weakness.

Peers on Argus

MBOT fell 2.44% with peers mostly lower as well (e.g., STXS -4.25%, KRMD -2.56%)...

MBOT fell 2.44% with peers mostly lower as well (e.g., STXS -4.25%, KRMD -2.56%), but no peers appeared in momentum scanners, suggesting a stock-specific move rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Conference showcase	Positive	-6.9%	LIBERTY showcased at Society of Interventional Oncology to drive adoption.
Jan 12	Milestones update	Positive	+1.9%	Reported 2025 progress and outlined 2026 commercial milestones for LIBERTY.
Nov 26	First hospital adoption	Positive	+21.8%	Emory University Hospital became first clinical adopter of LIBERTY system.
Nov 05	LMR launch	Positive	+5.0%	Announced start of U.S. limited market release for LIBERTY system.
Oct 16	Conference debut	Positive	-2.7%	Planned commercial debut of LIBERTY at interventional oncology symposium.

Pattern Detected

Commercialization and conference-related LIBERTY updates have often been positive catalysts, but reactions have been mixed, with both strong rallies and notable selloffs on generally positive news.

Recent Company History

Over the last few months, Microbot has transitioned LIBERTY from clearance to commercial rollout, moving from its clinical debut and limited market release in Q4 2025 to initial hospital adoption and 2026 milestone setting. Several announcements around FDA 510(k) clearance, limited market release, and Emory’s first-in-world adoption generated sizable moves (including a 21.81% gain on Nov 26, 2025), while other positive commercialization and conference updates saw selloffs. Today’s ISET-focused exposure continues this theme of conference-driven visibility and commercialization progress.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active shelf registration on Form S-3/A dated 2025-10-28, intended to become effective under Section 8(a). It has been used at least 2 times via 424B3 prospectus supplements filed on 2025-11-19, indicating established capacity to access capital markets if needed.

Market Pulse Summary

This announcement reinforces Microbot’s strategy of using major conferences to build clinical and co...

Analysis

This announcement reinforces Microbot’s strategy of using major conferences to build clinical and commercial momentum for LIBERTY, highlighting its status as an FDA-cleared, single-use, remotely operated system for peripheral endovascular procedures. Recent history shows a mix of strong rallies and selloffs around similar commercialization milestones, while regulatory filings detail active capital markets tools and ongoing rollout plans. Investors may watch adoption breadth across hospitals and the planned April 2026 full market release as key markers of execution.

Key Terms

endovascular, endovascular robotics, limited market release, single-use, +4 more

8 terms

endovascular medical

"International Symposium on Endovascular Therapy (ISET) conference, which took place..."

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

endovascular robotics medical

"Advances in Endovascular Robotics: Will There be a Role in the Future?"

Endovascular robotics are robotic systems that steer tiny tubes, wires and tools inside blood vessels during minimally invasive procedures, often from a console or with computer assistance. Like switching from hand-driving to GPS-assisted steering, they can make delicate vascular work more precise, reduce complications and radiation exposure, and enable procedures in more settings — factors that can expand market size, cut costs, and create new hardware, software and disposable revenue streams for investors.

limited market release technical

"LIBERTY® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US"

A limited market release is a staged launch of a product or service into a small group of customers, a specific region, or select sales channels before a full nationwide or global rollout. For investors it signals an early test of demand, production and distribution systems—like a pilot episode or a test drive—providing advance evidence about revenue potential, customer acceptance and the risks or costs of scaling up.

single-use technical

"The LIBERTY System, the only FDA cleared, single-use endovascular robotic system..."

Single-use describes a product designed to be used one time and then discarded or destroyed, like a disposable cup or a single-use syringe. For investors, it matters because these items create repeat sales of consumables, carry different regulatory and safety standards than reusable products, and can influence manufacturing costs, supply chain needs, liability exposure, and environmental or disposal responsibilities that affect a company’s profitability and risk profile.

remotely operated technical

"the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures"

Operated from a distance using communications links, controls or software rather than by someone physically present at the device or site. For investors, remotely operated systems can lower labor and travel costs, improve safety in hazardous locations, and enable faster scaling, but they also introduce dependency on connectivity, cybersecurity and remote-maintenance capabilities—risks that can affect reliability and long‑term costs.

peripheral endovascular medical

"remotely operated robotic system for peripheral endovascular procedures..."

Peripheral endovascular describes minimally invasive procedures that treat diseases of arteries and veins outside the heart—typically in the legs, arms or neck—by reaching the blood vessel from the inside using catheters, balloons, stents or similar tools to clear blockages or reinforce vessels without open surgery. Investors care because these techniques drive demand for specialized medical devices, affect procedure volumes, reimbursement and recovery times, and can shift market share much like fixing a clogged garden hose from the inside instead of digging it up.

interventional radiologists medical

"included leading interventional radiologists, interventional cardiologists, and vascular surgeons..."

Interventional radiologists are doctors who use medical imaging (like X‑rays, CT scans, or ultrasound) as a live “GPS” to guide thin instruments and small needles to treat conditions without open surgery. For investors, they matter because their techniques drive demand for specialized imaging machines, disposable devices and new minimally invasive therapies, influence hospital procedure mix and reimbursement trends, and can shorten recovery times that affect healthcare costs and patient volumes.

radiation exposure medical

"designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain"

Radiation exposure is the amount of ionizing energy from sources like X-rays, medical treatments, industrial equipment, or nuclear materials that people, products, or environments receive; think of it like sun exposure but from invisible high-energy rays that can damage cells over time. Investors care because excessive exposure can trigger health risks, regulatory fines, facility shutdowns, cleanup costs and liability claims, all of which can affect a company’s operations, reputation and financial outlook.

AI-generated analysis. Not financial advice.

International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics

LIBERTY^® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US

HINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that LIBERTY was featured at the International Symposium on Endovascular Therapy (ISET) conference, which took place February 9-12, 2026, in Miami Beach, Florida. The International Symposium on Endovascular Therapy brings together current and emerging endovascular experts to examine new techniques, technologies, and procedures that advance patient care.

During a Town Hall session, titled Advances in Endovascular Robotics: Will There be a Role in the Future?, which included leading interventional radiologists, interventional cardiologists, and vascular surgeons discussing real-world clinical experience, one of the featured agenda items focused on the future of single-use handheld vascular robots, which specifically highlighted the LIBERTY Endovascular Robotic System. The LIBERTY System, the only FDA cleared, single-use endovascular robotic system, was discussed prominently, highlighting its seamless workflow integration and features, which the Company believes will be key drivers for broader adoption and shape the next phase of peripheral endovascular intervention. As procedures become more complex and operator demands are expected to continue to grow, robotic assistance offers a potential solution to challenges many clinicians face daily.

“ISET plays a meaningful role in shaping the future of endovascular innovation, providing a platform where healthcare leadership and emerging technologies converge. We believe that LIBERTY’s inclusion in this important dialogue confirms the commercial traction of LIBERTY and reinforces our position among a prestigious group of interventional radiologists, vascular surgeons and other clinical decision makers,” commented Harel Gadot, President, CEO & Chairman. “To date, LIBERTY has been used across multiple hospitals for a wide range of procedure types, including complex cases. We have seen increased interest from physicians across several specialties within the same account and network of hospitals, including interventional radiology, interventional oncology, vascular surgery and interventional cardiology, which we believe is reinforcing its broad clinical relevance in the peripheral space and expanding overall commercial opportunity.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Commercialization Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation ISET

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What did Microbot Medical (MBOT) announce about LIBERTY at ISET Feb 9-12, 2026?

LIBERTY was featured in ISET discussions on single-use endovascular robotics and future roles. According to the company, speakers highlighted LIBERTY's workflow integration and clinical relevance across multiple specialties, reinforcing early commercial traction during the limited market release.

Is the LIBERTY system FDA cleared and available now for patients and hospitals (MBOT)?

Yes, LIBERTY is FDA cleared as a single-use endovascular robotic system. According to the company, it entered a limited market release in late 2025 with hospital use across several specialties, while broader availability is planned after a full release in April 2026.

What does MBOT say about LIBERTY's clinical use and specialties adopting it?

LIBERTY has been used in multiple hospitals across interventional radiology, vascular surgery, oncology, and cardiology. According to the company, this cross-specialty interest signals broad clinical relevance and potential to expand the commercial opportunity in peripheral interventions.

When will Microbot Medical (MBOT) plan the full market release of LIBERTY?

Microbot plans a full market release at the Society of Interventional Radiology conference in April 2026. According to the company, the SIR timing is intended to showcase LIBERTY and accelerate deeper market adoption following the limited release.

How does LIBERTY aim to benefit clinicians during peripheral endovascular procedures (MBOT)?

LIBERTY is designed for precise vascular navigation while reducing radiation exposure and physical strain for operators. According to the company, robotic assistance may help manage increasing procedural complexity and clinician ergonomic challenges.

What commercial progress did Microbot Medical (MBOT) report for LIBERTY during the ISET meeting?

The company reported increased physician interest and hospital deployments during its limited market release. According to the company, inclusion in ISET discussions reflects growing commercial traction and exposure among key clinical decision makers.